Business
Bharat Coking Coal IPO To List Tomorrow: GMP Indicates Over 50% Bumper Gains
Last Updated:
Bharat Coking Coal IPO, a Coal India subsidiary, lists on BSE and NSE January 19, 2026, with a strong GMP.
Bharat Coking Coal IPO: Listing Price Prediction. Shares to be listed tomorrow, January 19, 2026.
Bharat Coking Coal IPO Listing Price Prediction, GMP: The allotment of the Bharat Coking Coal IPO was concluded on January 14, 2026. Now, investors are eyeing the listing of the shares on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE), which is likely to take place on Monday, January 19, 2026.
The investors who have been allotted the unlisted shares of the Bharat Coking Coal IPO might be checking the grey market premium regularly.
The IPO was open for public subscription between January 9 and January 13. It received a massive overall subscription of 143.85 times subscription. Its retail category received 49.37x subscription, its non-institutional investor (NII) category received 240.49 times subscription, and its qualified institutional buyer (QIB) portion got 310.81 times bidding.
Bharat Coking Coal IPO Listing Date
The shares of Bharat Coking Coal Ltd (BCCL), a subsidiary of Coal India Ltd (CIL), will be listed on both the BSE and the NSE on January 19, Monday.
Bharat Coking Coal IPO Listing Price Prediction, GMP Today
According to market observers, unlisted shares of Bharat Coking Coal Ltd are currently trading at Rs 35.4 apiece in the grey market, which is a 53.91 per cent premium over the IPO price of Rs 23. It indicates a strong listing gains for investors. Its listing will take place on Monday, January 19.
The GMP is based on market sentiments and keeps changing. ‘Grey market premium’ indicates investors’ readiness to pay more than the issue price.
Bharat Coking Coal IPO Allotment Status
The Bharat Coking Coal IPO allotment has already been finalised.
The allotment status can be checked online by following these steps:
Via Official Registrar
1) Visit registrar Kfin Technologies’ portal – https://ipostatus.kfintech.com/.
2) Under ‘Select Company’, select ‘Bharat Coking Coal Limited’ from the drop-box.
3) Enter your application number, demat account, or permanent account number (PAN).
5) Then, click on the ‘Submit’ button.
Your share application status will appear on your screen.
Via the BSE
1) Go to the official BSE website via the URL — https://www.bseindia.com/investors/appli_check.aspx.
2) Under ‘Issue Type’, select ‘Equity’.
3) Under ‘Issue Name’, select ‘Bharat Coking Coal Limited’ in the drop box.
4) Enter your application number, or the Permanent Account Number (PAN). Those who want to check their allotment status via PAN can select the ‘Permanent Account Number’ option.
5) Then, click on the ‘I am not a robot’ to verify yourself and hit the ‘Search’ option.
Your share application status will appear on your screen.
Via NSE’s Website
The allotment status can also be checked on the NSE’s website at https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids.
Bharat Coking Coal IPO: More Details
According to the red herring prospectus (RHP), the maiden public issue is entirely an offer for sale (OFS) of 46.57 crore equity shares by Coal India.
The listing of BCCL is part of the government’s broader divestment push in the coal sector, aimed at unlocking value in Coal India’s subsidiaries and enhancing transparency through market discipline.
In its prospectus, the company stated that the IPO will help achieve the benefits of listing.
BCCL will make its stock market debut on January 16. The company said that half of the issue size has been reserved for qualified institutional buyers, 35 per cent for retail investors and the remaining 15 per cent for non-institutional investors.
Last year, Central Mine Planning and Design Institute Ltd (CMPDIL), another wholly-owned arm of Coal India, had also filed its draft papers with Sebi for an IPO via the OFS route.
While BCCL is a coal-producing entity, CMPDIL serves as Coal India’s technical and planning arm.
Bharat Coking Coal was the largest coking coal producer in India in fiscal 2025, according to a Crisil report. It produces various grades of coking coal, non-coking coal and washed coals for applications primarily in the steel and power industries.
The company was incorporated in 1972 to mine and supply coking coal concentrated in mines located at Jharia, Jharkhand and Raniganj, West Bengal coalfields.
The public sector firm has expanded operations significantly over the years, with coal production increasing from 30.51 million tonnes in fiscal 2022 to 40.50 million tonnes in fiscal 2025, which is an increase of 33 per cent. Its coal production stood at 15.75 million tonnes in the six months ended September 30, 2025, as compared to 19.09 million tonnes in the year-ago period.
The company operates a network of 34 operational mines, including 4 underground mines, 26 opencast mines, and 4 mixed mines as of September 30, 2025.
On the financial front, Bharat Coking Coal’s revenues from operations stood at Rs 13,802 crore and profit of Rs 1,204 crore in FY25.
BCCL’s issue comes against the backdrop of a blockbuster year for the primary market.
In 2025, companies raised a record nearly Rs 1.76 lakh crore through IPOs, buoyed by strong domestic liquidity, resilient investor sentiment and a supportive macroeconomic environment. This surpassed the Rs 1.6 lakh crore mobilised by 90 firms in 2024 and the Rs 49,436 crore raised by 57 companies in 2023.
Disclaimer: The views and investment tips by experts in this News18.com report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions.
Click here to add News18 as your preferred news source on Google.
January 18, 2026, 09:31 IST
Read More
Sarah has now got her money back but there are calls to reform the deadline for reporting scams to banks.
Source link
Music streamer Deezer allows users to filter out AI music, so why does Spotify not offer the same?
Source link
Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA.
Spencer Grant | Universal Images Group | Getty Images
Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U.S. Food and Drug Administration.
The company’s treatment uses Nobel Prize-winning technology Crispr to edit DNA and turn off the gene that controls production of a peptide that’s overactive in people with hereditary angioedema, causing them to experience potentially life-threatening swelling attacks. Intellia’s treatment is administered once through an hourslong infusion, making the edits directly in the liver.
Intellia said the one-time treatment reduced attacks by 87% compared with a placebo, meeting the study’s main goal. Six months after treatment, 62% of patients were free from attacks and weren’t using other therapies, Intellia said.
The company described the safety and tolerability of the treatment as “favorable,” reporting the most common side effects were infusion-related reactions, headaches and fatigue. Analysts were closely watching safety in the trial since a patient in a separate trial of a different treatment from Intellia died. That patient developed a liver injury and ultimately died from septic shock following an ulcer, according to the company.
“When you think about where we started with Crispr, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible, and we’ve had reports along the way in terms of milestones, but this is the first Phase 3 data in any indication with in vivo Crispr where you’re actually changing a gene that causes disease,” said Intellia CEO John Leonard.
The only FDA-approved Crispr-based medicine comes from Vertex Pharmaceuticals. Called Casgevy, the gene editing is done outside the body, or ex vivo. The process requires collecting a person’s blood cells, making the edits outside the body, then reinfusing them back into a patient. Intellia’s treatment, meanwhile, makes the edits inside the body, or in vivo.
Intellia said it has started a rolling application with the FDA and plans to complete the filing in the second half of this year. The company expects to launch the treatment in the U.S. in the first half of next year, if it’s approved.
If approved, Intellia’s treatment, lonvoguran ziclumeran, will compete with about a dozen other chronic drugs for HAE. Despite the allure of a one-time treatment, genetic medicines haven’t always been a commercial successes. BioMarin withdrew its gene therapy for Hemophilia A because of weak sales, for example.
Leonard said there are important differences between the two, like the fact that BioMarin’s therapy faced questions about how long the effects would last. In contrast, he said Intellia hasn’t seen a single case in almost six years where the effects diminished over time.
Despite the results, he’s reluctant to call Intellia’s treatment a functional cure.
“I think this is a tipping point for the disease and tipping point for Crispr-based in vivo therapy where you can make a change [and] it’s permanent,” Leonard said. “And, as far as we can tell, we don’t have a single patient in this program or other program where there’s been any waning of the effect of what we did to the gene or the effect of what we’ve seen with the clinical aspects of the disease itself. So it’s pretty exciting.”
Clarification: This story has been updated to clarify that a patient in a separate trial of a different treatment from Intellia developed acute liver injury and ultimately died from septic shock following an ulcer.
Why Spotify has no button to filter out AI music
‘I had £20,000 stolen and had to fight a 13-month fraud reporting rule to get it back’
King Charles and the Trumps unite at White House for a historic tea meeting
-
Sports1 week agoNCAA men’s gymnastics championship: All-time winners list
-
Sports1 week agoWWE WrestleMania 42 Night 2: Live match results and analysis
-
Fashion1 week agoUK’s Sosandar returns to profitability amid robust FY26 performance
-
Politics7 days agoUK’s Starmer seeks to deflect blame over Mandelson appointment
-
Entertainment1 week agoLee Anderson, Zarah Sultana kicked out of UK Parliament for calling PM ‘liar’
-
Business1 week agoHow Trump’s psychedelics executive order could unlock stalled cannabis reform
-
Business1 week agoNo fuel shortage: Govt assures 100% domestic LPG, PNG, CNG supply amid Hormuz energy crunch – The Times of India
-
Sports1 week agoQuetta Gladiators opt to bowl after winning toss against Peshawar Zalmi in PSL 11 clash